Table 1.

Measurements and standardized uptake values (SUV) pre‐ and post‐therapy for granulomatous lymphocytic interstitial lung disease (GLILD)

Area	Preimmunosuppression SUVmax	Post‐immunosuppression SUVmax	Preimmunosuppression linear measurement (cm)	Post‐immunosuppression linear measurement (cm)
L pharyngeal tonsil	9·2	4·7	n.a.	n.a.
R pharyngeal tonsil	8·9	5·4	n.a.	n.a.
R axilla LN	13·4	1·4	24	13
Subcarinal LN	14·8	2·6	26	14
RML lung nodule	6·1	1·5	9	7
RLL lung nodule	6·2	2·3	26	10
Inter‐aortocaval node	12·3	3	26	12
Left para‐aortic node	9·2	1·9	32	17
Right comm. iliac node	12·5	2·3	33	21
Liver	2·66	3·1	n.a.	n.a.
Mean disease SUVmax	10·29	2·79	n.a.	n.a.
Disease/liver ratio	3·87	0·9	n.a.	n.a.
Sum of measurable disease length	n.a.	n.a.	176	94
% Reduction	n.a.	77%	n.a.	47%

Table 1 sets out changes in the largest measurable lesions on the positron emission tomography (PET) and computed tomography (CT) components pre‐ and post‐treatment. SUV measurements are given for each pharyngeal tonsil, target lymph nodes in the right axilla, subcarinal space, inter‐aortocaval space, left para‐aortic space and right common iliac chain. Also measured are the two largest lung nodules in the right middle and lower lobes. 2‐[(18)F]‐fluoro‐2‐deoxy‐d‐glucose (FDG) uptake in the liver is given as an internal reference point for the two scans. The average SUV_max over the disease sites is given as well as the ratio of disease to liver activity both pre‐ and post‐treatment. The dimensions of all the anatomically measurable lesions are given in centimetres both pre‐ and post‐treatment. Following treatment the average SUV max has fallen by 73 and 77% when expressed as a ratio to liver uptake. The linear size of the lesions over the same period has reduced by only 47%. The lesions have reduced in size and metabolic activity, although reductions in metabolic activity are more marked.